IGF-I is a crucial cardiac survival factor that downregulating RhoA produces beneficial effects also mimicked by the Rho kinase inhibitor Y27632 and BH4, a finding indicating that the selective IGF-I overexpression may represent a therapeutic potential for DM-CMP (80). Here, IGF1 is linked to diabetes mellitus.